Table II.

Patient-reported outcomes in patients with plaque psoriasis versus palmoplantar psoriasis.

	Plaque psoriasis (N=1153)	Palmoplantar Psoriasis (N=66)	P-value
DLQI
DLQI, median (IQR)	3 (1, 6)	4 (1, 9)	0.037 a
DLQI category, N (%)			0.004 b
0-5 No-small effect	839 (73.5)	37 (56.1)
6-30 Moderate-extremely large effect	302 (26.5)	29 (43.9)
EQ-5D
EQ-5D index (U.S.) median (IQR)	0.84 (0.80, 1.0)	0.83 (0.75, 1.0)	0.022 a
EQ-5D Mobility c, N (%)			0.027 b
No problems	918 (79.8)	44 (67.7)
Problems	232 (20.2)	21 (32.3)
EQ-5D Self-care c, N (%)			0.019 b
No problems	1094 (95.0)	57 (87.7)
Problems	57 (5.0)	8 (12.3)
EQ-5D Usual Activities c, N (%)			<0.001 b
No problems	949 (82.5)	40 (61.5)
Problems	201 (17.5)	25 (38.5)
EQ-5D Pain/Discomfort c, N (%)			0.053 b
No problems	659 (57.3)	29 (44.6)
Problems	492 (42.7)	36 (55.4)
EQ-5D Anxiety/Depression c, N (%)			0.21 b
No problems	817 (71)	41 (63.1)
Problems	334 (29)	24 (36.9)
EQ-5D VAS score
Mean (SD)	78.1 (18.3)	74.3 (19.3)	0.098 d
Median (IQR)	80 (70, 90)	80 (70, 90)	0.072 a
Topical prescription use in the last week
Median number of days used (IQR)	3 (0, 7)	7 (1, 7)	0.001 a
Number of patients who reported no use, N (%)	416 (36.1)	15 (22.7)	0.033 b
Number of patients who reported heavy use (daily use with ≥ 2 applications per day), N (%)	158 (13.7)	23 (34.9)	<0.001 b

Significant values with P < 0.05 are shown in bold.

^aWilcoxon rank-sum test

^bFisher’s exact

^cOf the three possible responses for each EQ-5D dimension (no problems/some or moderate problems/severe problems), we combined responses to the moderate and severe categories to form two levels: no problems and problems.

^dStudent’s t-test